Nilubol Naris, Kebebew Electron
Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Cancer. 2015 Apr 1;121(7):1017-24. doi: 10.1002/cncr.29123. Epub 2014 Nov 25.
Some centers have advocated selecting patients with small papillary thyroid cancer (PTC) to undergo active surveillance without surgical treatment. The objectives of the current study were to analyze thyroid cancer (TC)-related mortality in a population-based cohort and to determine the impact of small PTCs (defined as tumors ≤ 2 cm in greatest dimension) on TC-related mortality.
Data on patients with TC of follicular cell origin from the National Cancer Institute's Surveillance, Epidemiology, and End Results 17 Registries database (1988-2007) were used to analyze the characteristics of PTCs ≤ 2 cm in patients who died from TC-related causes. The effects of clinical features on disease-specific survival were analyzed.
Over the 20-year study period, the rate of TC-related mortality was 2.8% (n = 1753 of 61,523 patients). Of the patients who died from TC-related causes, 38% had PTC, 10% had follicular TC, and 31.3% had anaplastic TC. PTCs ≤ 2 cm accounted for 12.3% of TC-related mortalities. Compared with patients who did not experience TC-related mortality from PTCs ≤ 2 cm, there were significantly higher rates of men (30% vs 17%; P < .01), patients aged ≥ 45 years (92% vs 52%; P < .01), tumors measuring >1 cm (59% vs 46%; P < .01), extrathyroid extension (41% vs 11%; P < .01), lymph node metastases (77% vs 28%; P < .01), and distant metastases (31% vs 1%; P < .01) among the patients who died from PTCs ≤ 2 cm. Independent risk factors for death from PTCs ≤ 2 cm included age ≥ 45 years, lymph node and distant metastases, extrathyroid extension, and undergoing less than thyroid lobectomy.
Because 12.3% of patients who experienced TC-related deaths had PTCs ≤ 2 cm despite undergoing thyroidectomy, the current results indicate that nonoperative management for patients who have PTCs ≤ 2 cm should be used with caution. Patients aged ≥ 45 years with PTCs ≤ 2 cm should undergo thyroidectomy.
一些中心主张选择小乳头状甲状腺癌(PTC)患者进行积极监测而非手术治疗。本研究的目的是分析基于人群队列中的甲状腺癌(TC)相关死亡率,并确定小PTC(定义为最大径≤2 cm的肿瘤)对TC相关死亡率的影响。
使用美国国立癌症研究所监测、流行病学和最终结果17个登记数据库(1988 - 2007年)中滤泡细胞源性TC患者的数据,分析死于TC相关原因的患者中最大径≤2 cm的PTC的特征。分析临床特征对疾病特异性生存的影响。
在20年的研究期间,TC相关死亡率为2.8%(61,523例患者中有1753例)。在死于TC相关原因的患者中,38%患有PTC,10%患有滤泡性TC,31.3%患有间变性TC。最大径≤2 cm的PTC占TC相关死亡病例的12.3%。与未因最大径≤2 cm的PTC发生TC相关死亡的患者相比,死于最大径≤2 cm的PTC的患者中男性比例显著更高(30%对17%;P <.01)、年龄≥45岁的患者比例更高(92%对52%;P <.01)、肿瘤直径>1 cm的比例更高(59%对46%;P <.01)、甲状腺外侵犯比例更高(41%对11%;P <.01)、淋巴结转移比例更高(77%对28%;P <.01)以及远处转移比例更高(31%对1%;P <.01)。最大径≤2 cm的PTC导致死亡的独立危险因素包括年龄≥45岁、淋巴结和远处转移、甲状腺外侵犯以及接受小于甲状腺叶切除术。
由于12.3%经历TC相关死亡的患者尽管接受了甲状腺切除术但仍患有最大径≤2 cm的PTC,当前结果表明,对于最大径≤2 cm的PTC患者应谨慎采用非手术治疗。年龄≥45岁且最大径≤2 cm的PTC患者应接受甲状腺切除术。